



Preferred Drug List

NEW DRUG REVIEW

Proprietary Name: Atripla®

Common Name: Efavirenz, Emtricitabine, and Tenofovir

PDL Category: Antiretrovirals

<u>Comparable Products</u>	<u>Preferred Drug List/ Recommended Drug List Status</u>
Emtriva®	Recommended
Sustiva®	Recommended
Viread®	Recommended

Summary

Indications and Usage: HIV-1 Infection

Dosage Forms: Tablets; 600/200/300mg

Recommended Dosage: 1 Tablet by mouth once daily

Common Adverse Drug Reactions: Lactic acidosis, dizziness, nausea, diarrhea, fatigue, headache, rash, insomnia

Contraindications: Hypersensitivity to any component of the product; coadministration with drugs containing lamivudine or St. John's Wort.

Manufacturer: Bristol-Myers Squibb and Gilead Sciences

Analysis: Atripla® is the first and only once-a-day tablet indicated for the treatment of HIV-1 infection. The product can be used as monotherapy or in combination with other antiretrovirals. While Atripla® has not demonstrated therapeutic superiority over other antiretrovirals, the triple cocktail tablet can improve compliance resulting in a lower incidence of drug-resistant strains of the virus. The combination of three active ingredients in one tablet will also result in only one copay for members to pay as compared to three. Due to the unique formulation of Atripla®, and the potential positive impact it can have on controlling HIV infection, this medication is a cost effective choice for management of HIV.

IME Recommendation:

<input type="checkbox"/> Preferred Drug	<input checked="" type="checkbox"/> Recommended Drug
<input type="checkbox"/> Non-Preferred Drug	<input type="checkbox"/> Non-Recommended Drug
<input type="checkbox"/> Preferred Drug with Conditions	